The influence of hormone therapies on type I and II endometrial cancer: A nationwide cohort study

• Published in: International journal of cancer Vol. 138; no. 6; pp. 1506 - 1515
• Main Authors: Mørch, Lina S., Kjær, Susanne K., Keiding, Niels, Løkkegaard, Ellen, Lidegaard, Øjvind
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 15.03.2016
• Subjects: Aged; Cancer; Cohort Studies; Denmark - epidemiology; Endometrial cancer; Endometrial Neoplasms - epidemiology; Endometrial Neoplasms - etiology; Estrogens; Female; Hormone replacement therapy; Hormone Replacement Therapy - adverse effects; hormone therapy; Humans; Incidence; Medical research; Menopause; Middle Aged; Odds Ratio; Population Surveillance; Registries; Risk Factors; Time Factors; types of endometrial cancer; types of hormone replacement therapy; Denmark; endometrial cancer; types of hormone replacement therapy; types of endometrial cancer; hormone therapy
• ISSN: 0020-7136; 1097-0215
• DOI: 10.1002/ijc.29878

The influence of hormone therapy (HT) on risk for endometrial cancer is still casting which type of HT the clinicians recommend. It is unrevealed if HT has a differential influence on Type I versus Type II endometrial tumors, and little is known about the influence of, e.g., different routes of administration and about the influence of tibolone. We followed all Danish women aged 50–79 years without previous cancer or hysterectomy (n = 914,595) during 1995–2009. From the National Prescription Register, we computed HT exposures as time‐dependent covariates. Incident endometrial cancers (n = 6,202) were identified from the National Cancer Registry: 4,972 Type I tumors and 500 Type II tumors. Incidence rate ratios (RRs) and 95% confidence intervals (Cls) were estimated by Poisson regression. Compared with women never on HT, the RR of endometrial cancer was increased with conjugated estrogen: 4.27 (1.92–9.52), nonconjugated estrogen: 2.00 (1.87–2.13), long cycle combined therapy: 2.89 (2.27–3.67), cyclic combined therapy: 2.06 (1.88–2.27), tibolone 3.56 (2.94–4.32), transdermal estrogen: 2.77 (2.12–3.62) and vaginal estrogen: 1.96 (1.77–2.17), but not with continuous combined therapy: 1.02 (0.87–1.20). In contrast, the risk of Type II tumors appeared decreased with continuous combined therapy: 0.45 (0.20–1.01), and estrogen therapy implied a nonsignificantly altered risk of 1.43 (0.85–2.41). Our findings support that continuous combined therapy is risk free for Type I tumors, while all other hormone therapies increase risk. In contrast, Type II endometrial cancer was less convincingly associated with hormone use, and continuous combined therapy appeared to decrease the risk. What's new? Type I endometrial cancer is driven by hormone‐dependent mechanisms, which are sensitive to estrogen therapy. Type II disease, on the other hand, is known to be less hormone‐dependent, though the degree to which hormones influence type II tumor risk remains unclear. In this nationwide cohort study, estrogen therapy was found to have little impact on risk of type II endometrial cancer, while continuous combined estrogen‐progestin therapy was associated with an apparent decline in risk. By contrast, all hormone therapies, with the exception of continuous combined therapy, raised the risk of type I tumors.